Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Drug crawled date : 2021 - 05 - 20 save search
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment of Completely Resected Esophageal or Gastroesophageal Junction Cancer in Patients who have Received Neoadjuvant Chemoradiotherapy
Published: 2021-05-20 (Crawled : 22:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.35%
H: 2.92%
C: 2.57%
food treatment therapy cancer drug iot nivolumab
Drug Trial Snapshot: TEGSEDI
Published: 2021-05-20 (Crawled : 16:03) - fda.gov
IONS | $41.85 1.9% 1.86% 630K
|
Health Technology
|
| O: 0.14%
H: 5.31%
C: 3.25%
trial drug
Drug Trial Snapshot: FIRDAPSE
Published: 2021-05-20 (Crawled : 15:39) - fda.gov
CPRX | News | $14.73 -2.45% -2.51% 990K
|
Health Technology
|
| O: 0.13%
H: 2.57%
C: 0.77%
trial drug
Drug Trial Snapshot: DAURISMO
Published: 2021-05-20 (Crawled : 15:21) - fda.gov
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: -0.25%
H: 1.31%
C: 0.98%
trial drug
Global Roundup: Russia-Developed RA Drug Shows Significant Promise in Phase III Study
Published: 2021-05-20 (Crawled : 15:00) - biospace.com/
BDX | $234.36 0.21% 0.0% 800K
|
Health Technology
|
| O: -0.41%
H: 1.51%
C: 1.3%
MIST | $1.67 2.45% 2.4% 90K
|
Health Technology
|
| O: -0.37%
H: 2.21%
C: 0.18%
GLPG | News | $29.47 1.38% 1.36% 120K
|
Health Technology
|
| O: 0.19%
H: 2.85%
C: 2.1%
russia drug
Global Roundup: Russia-Developed RA Drug Shows Significant Promise in Phase I...
Published: 2021-05-20 (Crawled : 14:00) - biospace.com/
BDX | $234.36 0.21% 0.0% 800K
|
Health Technology
|
| O: -0.41%
H: 1.51%
C: 1.3%
MIST | $1.67 2.45% 2.4% 90K
|
Health Technology
|
| O: -0.37%
H: 2.21%
C: 0.18%
GLPG | News | $29.47 1.38% 1.36% 120K
|
Health Technology
|
| O: 0.19%
H: 2.85%
C: 2.1%
russia drug
Global Roundup: UK-Developed RA Drug Shows Significant Promise in Phase III S...
Published: 2021-05-20 (Crawled : 13:00) - biospace.com/
BDX | $234.36 0.21% 0.0% 800K
|
Health Technology
|
| O: -0.41%
H: 1.51%
C: 1.3%
MIST | $1.67 2.45% 2.4% 90K
|
Health Technology
|
| O: -0.37%
H: 2.21%
C: 0.18%
GLPG | News | $29.47 1.38% 1.36% 120K
|
Health Technology
|
| O: 0.19%
H: 2.85%
C: 2.1%
drug
Sorrento Reports Positive Initial Result in Dosing of First Enbrel-Non-Responding Rheumatoid Arthritis Patient With the Sofusa® Lymphatic Drug Delivery Device
Published: 2021-05-20 (Crawled : 02:00) - globenewswire.com
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 1.43%
H: 4.24%
C: 1.98%
rheumatoid arthritis positive drug device drug delivery liver
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.